Table 3

Association of algorithm detected tumour-infiltrating lymphocytes (TILs) with clinicopathological characteristics

VariablesAll patientsSeminomasNon-seminomas
Number of patients (%)TILs/mm2 (median)P valuesNumber of patients (%)TILs/mm2 (median)P valuesNumber of patients (%)TILs/mm2 (median)P values
All patients89 (100)100959 (100)128830 (100)428
Tumour type
 Seminoma59 (66)12880.003
 Non-seminoma30 (34)428
Laterality
 Unilateral84 (94)9930.9454 (92)14050.3830 (100)428
 Bilateral5 (6)11595 (8)1159
Tumour size
 ≤40 mm54 (61)9330.6232 (54)20370.0622 (73)4470.93
 >40 mm30 (34)99322 (37)10578 (27)381
 NA5 (6)5 (8)
Clinical stage at presentation
 170 (79)11320.0246 (78)15520.00324 (80)4220.57
 2–316 (18)47110 (17)5436 (20)446
 NA3 (3)3 (5)
Pathological T stage (pT)
 pT164 (72)10570.0950 (85)14050.2314 (47)3750.41
 pT2–323 (26)7267 (12)72616 (53)628
 NA2 (2)2 (3)
Lymphovascular invasion
 Not detected66 (74)11320.0151 (86)14470.0515 (50)4160.82
 Detected21 (24)4806 (10)60315 (50)465
 NA2 (2)2 (3)
Rete testis invasion
 Not detected41 (46)11040.8425 (42)20130.0316 (53)3270.10
 Detected42 (47)97428 (47)99314 (47)862
 NA6 (7)6 (10)
Adjuvant treatment at presentation
 No adjuvant42 (47)8620.2519 (32)20590.0823 (77)4160.44
 Single carboplatin25 (28)124225 (42)1242
 Radiotherapy2 (2)9462 (3)946
 Bleomycin, etoposide and cisplatin (BEP) or etoposide and cisplatin (EP)13 (15)4777 (12)6086 (20)446
 NA5 (6)11594 (7)10841 (3)2201
Outcome status
 Not relapsed71 (80)11040.0649 (83)14820.1322 (73)4400.96
 Relapsed15 (17)8077 (12)8788 (27)428
 NA3 (3)3 (5)
  • NA, not applicable.